Keyphrases
Advanced Solid Tumors
100%
Myeloid-derived Suppressor Cells
100%
Plasmablastic Lymphoma
66%
5-fluorouracil (5-FU)
66%
Mogamulizumab
66%
Cytotoxic T Lymphocytes
55%
Tumor
46%
Tumor Growth
41%
Tumor-infiltrating
38%
Malignancy
38%
In Cancer
36%
Interferon Regulatory Factor 8 (IRF8)
35%
Colon Adenocarcinoma
33%
Patients with Advanced Cancer
33%
Nivolumab
33%
Metastatic Tumor
33%
Central Nervous System Involvement
33%
Phase II Study
33%
Cytologic Findings
33%
Immune Escape
33%
Granzyme B
33%
Primary Leiomyosarcoma
33%
Interferon-β (IFN-β)
33%
Deregulation
33%
β-adrenoceptor
33%
Gastrointestinal Stromal Tumor
33%
Stem Cells
33%
Apoptotic Factors
33%
Tumor Growth in Vivo
33%
Phase I Study
33%
Navoximod
33%
Cytochrome P450 2D6 (CYP2D6)
33%
Panobinostat
33%
Type I Interferon
33%
Lipids
33%
Gastrointestinal Tract
33%
Plasma Cell Infiltration
33%
Fas Expression
33%
Indoleamine 2,3-dioxygenase 1 Inhibitor
33%
Hepatic Failure
33%
Apoptotic Resistance
33%
H3K9 Methylation
33%
Receptor 1
33%
Bcl-xL
33%
CD133
33%
Advanced or Metastatic
33%
Inhibitory Effect
33%
Nanoparticle Delivery
33%
Unusual Presentation
33%
Multiple Myeloma
33%
Immunology and Microbiology
Myeloid-Derived Suppressor Cell
100%
Colon
66%
STAT3
66%
IRF8
52%
Cytotoxic T Cell
47%
Mouse
41%
Myeloid
35%
Immune Escape
33%
Beta Interferon
33%
Interferon Alfa
33%
Granzyme B
33%
interferon
33%
Drug Resistance
33%
Cancer Stem Cell
33%
Central Nervous System
33%
Tremelimumab
33%
Mogamulizumab
33%
Durvalumab
33%
Necroptosis
33%
Promoter Region
29%
Human Herpesvirus 8
22%
Cancer Cell
17%
STAT1
16%
Chromatin Immunoprecipitation
11%
Epigenetics
11%
Overall Survival
11%
Human Immunodeficiency Virus
11%
T Cell
10%
Tumor Cell
10%
Immunosurveillance
10%
Wild Type
9%
Antigen Specificity
8%
Regulatory T Cell
8%
Microorganism
8%
CCR4
8%
T Cell Activation
8%
T Cell Receptor
8%
Immune Response
8%
Transcription Factor RelB
8%
Knockout Mouse
7%
Immune Evasion
6%
Cell Death
6%
DNA Methylation
6%
Mouse Model
5%
Gene Expression Profiling
5%
Fas Receptor
5%
Mediator
5%
Pharmacology, Toxicology and Pharmaceutical Science
Solid Malignant Neoplasm
100%
Mogamulizumab
66%
Neoplasm
63%
Malignant Neoplasm
47%
Tumor Growth
37%
Nivolumab
33%
Advanced Cancer
33%
Navoximod
33%
Panobinostat
33%
CYP2D6
33%
Nanoparticle
33%
Fluorouracil
33%
Indoleamine 2,3 Dioxygenase
33%
Colon Cancer
33%
Durvalumab
33%
Tremelimumab
33%
Plasmablastic Lymphoma
33%
Virus Etiology
33%
Colon Tumor
33%
Disease
28%
Mouse
22%
Dextromethorphan
20%
1,2 Dioleoyl 3 Trimethylammoniopropane
19%
Tolerability
17%
Interferon Consensus Sequence Binding Protein
16%
Kynurenine
16%
Second Cancer
13%
Human Herpesvirus 8
13%
Pharmacodynamics
13%
Overall Survival
11%
Colorectal Cancer
9%
Chemotherapy
9%
Elimination
8%
Antitumor Activity
8%
Tumor Necrosis Factor Receptor Superfamily Member 6
8%
Tryptophan
8%
Adverse Event
8%
HIV
6%
Lung Cancer
6%
Endometrium Cancer
6%
Dextrorphan
6%
Lymphocytic Lymphoma
6%
Etiology
6%
